A urine DNA test to detect aggressive prostate cancer
EpiCapture-prostate selectively detects aggressive prostate cancer (Gleason grade 4 disease). It measures epigenetic changes at six genes in urine using a PCR platform to generate an EpiCapture-prostate score, the likelihood that a person has aggressive prostate cancer. The initial intended use is as a disease monitoring tool for patients who have been diagnosed with low-/favourable-intermediate-risk prostate cancer (i.e. people on Active Surveillance), to be used repeatedly to keep a check on disease progression. Future intended use is as an early detection test.